文献速递淋巴瘤

维布妥昔单抗联合AVD方案治疗霍奇金淋巴瘤:多中心队列中外周神经病变的发生率与管理

Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort.
PubMed 文献 · Blood Adv · 2023-01-01

这项多中心回顾性研究分析了153例接受维布妥昔单抗联合AVD方案一线治疗新诊断经典霍奇金淋巴瘤的患者,其中34例(22%)不符合ECHELON-1试验入组标准;治疗期间80%报告外周神经病变,44%因之外调整维布妥昔单抗(23%停药、17%减量、4%暂停),中位随访24个月时36%记录到神经病变完全缓解、33%改善;晚期患者2年无进展生存率为82.7%(95%CI 0.76-0.90),总生存率为97.4%(95%CI 0.94-1.00)。

要点

  • 治疗期间80%患者报告外周神经病变,其中1级39%、2级31%、3级10%。
  • 44%患者因外周神经病变调整维布妥昔单抗:停药23%、减量17%、暂停4%。
  • 因外周神经病变停用维布妥昔单抗的患者无进展生存未更差。

核心结论

  • 在非试验环境中,维布妥昔单抗联合AVD方案与较高的外周神经病变发生率相关,维布妥昔单抗停药率高于既往报告,但2年结局仍具可比性。

研究设计与样本

  • 多中心回顾性研究,纳入10家美国机构的153例新诊断经典霍奇金淋巴瘤患者。
  • 34例(22%)至少存在1项ECHELON-1试验排除标准,包括分期、体能状态和合并症。

主要发现

  • 治疗期间80%患者报告外周神经病变:1级39%、2级31%、3级10%。
  • 44%患者因外周神经病变调整维布妥昔单抗:停药23%、减量17%、暂停4%。
  • 中位随访24个月,末次随访时36%记录到外周神经病变完全缓解,33%记录到改善。
  • 晚期患者2年无进展生存率为82.7%(95%CI 0.76-0.90),总生存率为97.4%(95%CI 0.94-1.00)。
  • 因外周神经病变停用维布妥昔单抗的患者无进展生存未更差。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Brentuximab vedotin (BV) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) is increasingly used for frontline treatment of stage III/IV classical Hodgkin lymphoma (cHL). Peripheral neuropathy (PN) was the most common and treatment-limiting side effect seen in clinical trials but has not been studied in a nontrial setting, in which clinicians may have different strategies for managing it. We conducted a multisite retrospective study to characterize PN in patients who received BV + AVD for newly diagnosed cHL. One hundred fifty-three patients from 10 US institutions were eligible. Thirty-four patients (22%) had at least 1 ineligibility criteria for ECHELON-1, including stage, performance status, and comorbidities. PN was reported by 80% of patients during treatment; 39% experienced grade (G) 1, 31% G2, and 10% G3. In total, BV was modified in 44% of patients because of PN leading to BV discontinuation in 23%, dose reduction in 17%, and temporary hold in 4%. With a median follow-up of 24 months, PN resolution was documented in 36% and improvement in 33% at the last follow-up. Two-year progression-free survival (PFS) for the advanced-stage patients was 82.7% (95% confidence interval [CI], 0.76-0.90) and overall survival was 97.4% (95% CI, 0.94-1.00). Patients who discontinued BV because of PN did not have inferior PFS. In the nontrial setting, BV + AVD was associated with a high incidence of PN. In our cohort, which includes patients who would not have been eligible for the pivotal ECHELON-1 trial, BV discontinuation rates were higher than previously reported, but 2-year outcomes remain comparable.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bowers JT, Anna J, Bair SM, et al. Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort. Blood Adv. 2023. PMID: 37595053. doi:10.1182/bloodadvances.2023010622

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。